V - Med BPC-157 Vial 5mg

BPC 157 5mg, also known as Body Protection Compound-157 or Bepecin, is a pentadecapeptide derived from a protective protein in human gastric juice. Each vial contains 5mg of lyophilized BPC 157, requiring reconstitution with bacteriostatic water for research use via subcutaneous or intramuscular injection. In animal studies, it demonstrates cytoprotective, regenerative, and anti-inflammatory effects, accelerating healing of muscles, tendons, ligaments, skin, and the gastrointestinal tract, while protecting organs like the liver and pancreas.

Research highlights BPC 157’s ability to enhance angiogenesis (blood vessel formation), increase collagen and reticulin formation, and stimulate macrophage and fibroblast activity, making it a potential therapeutic for wound healing, burns, and conditions like leaky gut, IBS, and ulcers. It shows promise in counteracting trauma-induced damage, reducing inflammation, and supporting neural and cardiovascular health, though human data is limited. Anecdotal reports on X suggest benefits for gut health, mood, and minor injuries, but these are inconclusive without clinical trials. Concerns exist about promoting vascular growth, which could exacerbate undiagnosed tumors, necessitating caution in research.

Benefits

• Accelerates healing of muscles, tendons, ligaments, and skin in animal studies

• Reduces inflammation and protects organs (e.g., liver, pancreas, gut)

• Enhances angiogenesis and collagen formation for wound repair

• Supports gastrointestinal health (e.g., ulcers, IBS, leaky gut)

• May improve neural and cardiovascular function, per preclinical data

• Exhibits analgesic effects and minimal toxicity in animal models

Side effects

Despite its benefits, BPC 157 5mg may cause the following side effects:

• Mild irritation or redness at the injection site

• Potential headaches or fatigue in research subjects

• Risk of promoting vascular growth in undiagnosed tumors

• Possible digestive upset or immune response in rare cases

• Contamination risks if sterile techniques are not followed

• Banned by WADA, posing risks for athletes in drug testing

These can be managed by using sterile equipment, rotating injection sites, and adhering to research protocols. Lack of human clinical data increases uncertainty.

Dosages & Protocol

Dosages:

• Beginner: 200–250mcg per day, via subcutaneous or intramuscular injection

• Intermediate: 250–400mcg per day, adjusted per study objectives

• Advanced: 400–500mcg per day, under strict research oversight

Reconstitute with 2ml bacteriostatic water to yield 2500mcg/ml (2.5mg/ml). For a 250mcg dose, draw 0.1ml (10 units on a 1ml insulin syringe). Administer once daily, preferably near the injury site (subcutaneous) or muscle (intramuscular), rotating sites. Conduct 4–12 week cycles, with vial usage of ~2–3 vials for 250mcg/day over 8 weeks. Use within 30 days post-reconstitution and store at 2–8°C.

How to administer – reconstitution and how to inject

BPC 157 5mg is provided as a lyophilized powder requiring reconstitution with bacteriostatic water.

Reconstitution:

• Disinfect vial and bacteriostatic water ampule stoppers with an alcohol swab

• Draw 2ml bacteriostatic water into a sterile syringe

• Inject water slowly along the vial wall at a 45° angle to avoid foaming

• Gently swirl (do not shake) until fully dissolved

• Store reconstituted solution at 2–8°C, use within 30 days

Injection:

• Use a 1ml insulin syringe with a 30-gauge needle

• Draw 0.08–0.2ml (8–20 units) for 200–500mcg doses

• Clean the injection site (e.g., abdomen, thigh, near injury) with an alcohol swab

• Inject subcutaneously (45–90° angle, pinching skin) or intramuscularly

• Inject slowly and rotate sites to minimize irritation

• Use a new sterile syringe for each injection

Storage

• Store lyophilized vial at -20°C for long-term or 4°C for short-term use

• Store reconstituted solution at 2–8°C, away from light and heat

• Avoid freeze-thaw cycles; use within 30 days of reconstitution

• Keep vial and ampule sealed tightly when not in use

Half life & detectability

Half-Life: Approximately 4–6 hours, with regenerative effects persisting longer due to receptor activation.Detection Time: Detectable in urine for up to 1–2 weeks, depending on dosage, metabolism, and testing sensitivity. BPC 157 is banned by WADA under the S0 category.

For athletes subject to drug testing, it is important to consider these detection times and plan accordingly to avoid positive tests for banned substances.